The discovery and development of boceprevir

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Introduction: Boceprevir was the first direct acting agent developed for the treatment of hepatitis C virus infection. Boceprevir functions by targeting NS3 protease, a viral enzyme essential for replication. This peptidomimetic molecule was optimized from a peptide lead to provide a potent, selective and orally bioavailable drug that can be combined with ribavirin and peg interferon to achieve sustained viral response (undetectable HCV RNA levels for 24 weeks after completion of therapy) in patients infected with Genotype 1 of the virus. Areas covered: This article provides a review of the pre-clinical and clinical discovery of boceprevir. This review includes the role and function of its molecular target, NS3 protease, as well as the assays used to measure in vitro efficacy, compound optimization and clinical studies to demonstrate safety and efficacy. Expert opinion: As the first direct acting anti-HCV agent, boceprevir represents an important advance in therapy of this widespread chronic disease. Yet, while this therapy is a valuable approach, it does have limitations. Studies have suggested that 30% of patients do not achieve sustained viral response and 11% of patients have developed anemia and/or neutropenia. Current drug discovery and development efforts are underway to develop novel therapeutic options that address these issues.

Original languageEnglish
Pages (from-to)1439-1447
Number of pages9
JournalExpert Opinion on Drug Discovery
Volume8
Issue number11
DOIs
StatePublished - 1 Nov 2013

Fingerprint

Peptide Hydrolases
Peptidomimetics
Therapeutics
Ribavirin
Expert Testimony
Virus Diseases
Drug Discovery
Neutropenia
Hepacivirus
Interferons
Anemia
Chronic Disease
Genotype
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
RNA
Viruses
Safety
Peptides
Enzymes
Pharmaceutical Preparations

Keywords

  • Antiviral agent
  • Boceprevir
  • NS3 protease
  • Peptidomimetic
  • Protease inhibitor

Cite this

@article{0338c62bfd6e4cdcb4f28fff2cf585b5,
title = "The discovery and development of boceprevir",
abstract = "Introduction: Boceprevir was the first direct acting agent developed for the treatment of hepatitis C virus infection. Boceprevir functions by targeting NS3 protease, a viral enzyme essential for replication. This peptidomimetic molecule was optimized from a peptide lead to provide a potent, selective and orally bioavailable drug that can be combined with ribavirin and peg interferon to achieve sustained viral response (undetectable HCV RNA levels for 24 weeks after completion of therapy) in patients infected with Genotype 1 of the virus. Areas covered: This article provides a review of the pre-clinical and clinical discovery of boceprevir. This review includes the role and function of its molecular target, NS3 protease, as well as the assays used to measure in vitro efficacy, compound optimization and clinical studies to demonstrate safety and efficacy. Expert opinion: As the first direct acting anti-HCV agent, boceprevir represents an important advance in therapy of this widespread chronic disease. Yet, while this therapy is a valuable approach, it does have limitations. Studies have suggested that 30{\%} of patients do not achieve sustained viral response and 11{\%} of patients have developed anemia and/or neutropenia. Current drug discovery and development efforts are underway to develop novel therapeutic options that address these issues.",
keywords = "Antiviral agent, Boceprevir, NS3 protease, Peptidomimetic, Protease inhibitor",
author = "David Rotella",
year = "2013",
month = "11",
day = "1",
doi = "10.1517/17460441.2013.843525",
language = "English",
volume = "8",
pages = "1439--1447",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "11",

}

The discovery and development of boceprevir. / Rotella, David.

In: Expert Opinion on Drug Discovery, Vol. 8, No. 11, 01.11.2013, p. 1439-1447.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The discovery and development of boceprevir

AU - Rotella, David

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Introduction: Boceprevir was the first direct acting agent developed for the treatment of hepatitis C virus infection. Boceprevir functions by targeting NS3 protease, a viral enzyme essential for replication. This peptidomimetic molecule was optimized from a peptide lead to provide a potent, selective and orally bioavailable drug that can be combined with ribavirin and peg interferon to achieve sustained viral response (undetectable HCV RNA levels for 24 weeks after completion of therapy) in patients infected with Genotype 1 of the virus. Areas covered: This article provides a review of the pre-clinical and clinical discovery of boceprevir. This review includes the role and function of its molecular target, NS3 protease, as well as the assays used to measure in vitro efficacy, compound optimization and clinical studies to demonstrate safety and efficacy. Expert opinion: As the first direct acting anti-HCV agent, boceprevir represents an important advance in therapy of this widespread chronic disease. Yet, while this therapy is a valuable approach, it does have limitations. Studies have suggested that 30% of patients do not achieve sustained viral response and 11% of patients have developed anemia and/or neutropenia. Current drug discovery and development efforts are underway to develop novel therapeutic options that address these issues.

AB - Introduction: Boceprevir was the first direct acting agent developed for the treatment of hepatitis C virus infection. Boceprevir functions by targeting NS3 protease, a viral enzyme essential for replication. This peptidomimetic molecule was optimized from a peptide lead to provide a potent, selective and orally bioavailable drug that can be combined with ribavirin and peg interferon to achieve sustained viral response (undetectable HCV RNA levels for 24 weeks after completion of therapy) in patients infected with Genotype 1 of the virus. Areas covered: This article provides a review of the pre-clinical and clinical discovery of boceprevir. This review includes the role and function of its molecular target, NS3 protease, as well as the assays used to measure in vitro efficacy, compound optimization and clinical studies to demonstrate safety and efficacy. Expert opinion: As the first direct acting anti-HCV agent, boceprevir represents an important advance in therapy of this widespread chronic disease. Yet, while this therapy is a valuable approach, it does have limitations. Studies have suggested that 30% of patients do not achieve sustained viral response and 11% of patients have developed anemia and/or neutropenia. Current drug discovery and development efforts are underway to develop novel therapeutic options that address these issues.

KW - Antiviral agent

KW - Boceprevir

KW - NS3 protease

KW - Peptidomimetic

KW - Protease inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84886602795&partnerID=8YFLogxK

U2 - 10.1517/17460441.2013.843525

DO - 10.1517/17460441.2013.843525

M3 - Review article

C2 - 24079543

AN - SCOPUS:84886602795

VL - 8

SP - 1439

EP - 1447

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 11

ER -